


The Future of Meat Starts with Cells



Highlights

- 1 Early commercial traction: Revenue from completed cell-engineering projects
- 2 Global validation: Cell lines under evaluation across five countries
- 3 Secured pre-seed investments from a leading international food-tech organization and the State of DE
- 4 Led by a PhD cell engineer with 25+ years of relevant experience
- 5 Capital-light by design: Small lab, lean team, globally licensed cell lines

Featured Investors



ProVeg International, Inc.

Follow

ProVeg International is a global food-system organization with 250+ employees across 14 countries. It works with companies, investors, policymakers and innovators to accelerate the shift toward more sustainable food and alternative proteins.

Devika Suresh, Head of Incubator

"Through the ProVeg Incubator, we invested in Livestock Labs because they are tackling one of cultivated meat's foundational challenges: the cells themselves. We believe their technology could help producers deliver higher-quality meat at a lower cost, giving Livestock Labs an important role in the industry's growth."



Delaware Economic Development Authority (DEDA)

Follow

The Delaware Economic Development Authority is the State of Delaware's financing authority supporting business growth, innovation and job creation through investments and incentive programs for high-impact companies across the state.

C.J. Bell, Director

"Livestock Labs is doing exactly what we hope to see out of DASCP: a science-first team building hard technology in Delaware instead of somewhere else. Their cell-line work is a real bet on where the cultivated meat industry is headed, and we're glad to be one of the investors backing it."



Nidal Barake

Syndicate Lead

Follow

Invested \$110,000

Entrepreneur and investor focused on the food industry. He invests across the food ecosystem, including food tech, restaurants, retail, and digital platforms. He founded Gluttonomy, a food-focused strategy and creative agency, and Lengua Conference gluttonomy.com

"I'm investing in Livestock Labs because I believe cultivated meat has the potential to fundamentally transform how we produce and consume food. But for the industry to fulfill that promise, it needs more than great ideas; it needs the infrastructure, technology, and capabilities to scale. I see Livestock Labs as an important engine for that growth, helping companies overcome critical barriers and move cultivated meat

from an emerging technology into a viable, scalable, and impactful industry."



Walter Sinnott-Armstrong

Follow

Duke University's Chauncey Stillman Distinguished Professor of Practical Ethics. Appointments in Philosophy, Law, and Psychology and Neuroscience. Author of 8 books and 250+ articles. Expert on AI ethics, moral psychology, and political polarization.

"I invested in Livestock Labs happily because it offers a rare opportunity to make money, reduce animal suffering, slow climate change, and fuel scientific progress—all at once. By focusing on developing better cells, Livestock Labs has found a fulcrum point that can help make cultivated meat affordable, delicious, and commercially viable at scale. What more could you want?"

Team



Steen Ooi Founder, Chief Executive Officer, Chief Scientific Officer

Genome engineer and cell biologist with 25+ years of experience. Former New Age Eats cell-engineering lead, ex-UCL/Columbia/UCLA researcher, ERC grant recipient, and published in Nature, Science, and Cell.

[scholar.google.com](https://scholar.google.com/citations?user=...)



Andrew Sayles Co-Founder and Chief Operating Officer

Commercial operator with experience building two cultivated-meat companies. Early hire at Mission Barns, the first to sell FDA- and USDA-cleared cultivated pork. At Livestock Labs, he helped secure grants, state backing, paid projects and global pilots.

[in](#) [x](#)

Memo



LIVESTOCK LABS

Where Next-Gen Animal Products Begin

We engineer cells to enable lower-cost, higher-quality animal products.

THE INVESTMENT THESIS

Small Cells. Massive Opportunity.

Billions have been invested proving cultivated meat and other cell-based animal products are possible. The next era is specialization. High-performing cells are the foundation: they shape product quality, production costs, and the ability to scale. Livestock Labs engineers, owns, and continuously upgrades these cells, licensing the same lines across multiple customers and industries. Investing now offers the opportunity to share in the value we build supplying the essential cells behind the transformation of trillion-dollar markets.

Revenue Generated

Custom cell engineering projects

5 Countries

Evaluating our cells
US • Canada • India • Japan • Singapore

Backed By



Capital-light By Design

Small lab.
Small team.
Global licensing model.

25+ Years

Relevant cell engineering experience

THE PROBLEM

Meat Demand is Growing. The Current System is Already Stretched.


The world wants more meat. But land and resources are finite. Livestock already occupies most of the world's agricultural land, while forests and wildlife habitats continue to be cleared for pasture and animal feed. Nearly 88 billion land animals are slaughtered every year, yet demand is still rising. Simply scaling yesterday's system is not a tenable solution to address tomorrow's demands.



THE UPGRADE

Grow the meat. Not the animal.

Cultivated Meat: More Control. More Possibilities



Illustrative process. Capabilities vary by product, process, and scale.

THE BOTTLENECK


Cultivated Meat Is Possible. Making It Economical Is the Challenge.

Reaching industrial scale depends on three core levers: the cost of feeding cells, bioprocess design, and cell-line performance.

Cell lines sit at the foundation. Their growth, efficiency, stability, and product traits can create compounding effects throughout the system, reducing the burden on media and bioprocessing while improving final-product quality.

Without access to robust cell lines, companies must commit specialized technical talent, years of development, and millions of dollars to this single component before they can focus on the product they actually want to bring to market.

The Compounding Effect of Cells




THE SOLUTION

Engineering Cells by Design

Livestock Labs' platform methodically builds critical performance traits into animal cells. The result is controllable, upgradeable cell lines designed to lower costs, improve quality, and help producers make the animal products people already love more efficiently, sustainably, and responsibly.

Precision Architecture for Cell Engineering




THE ECONOMICS

Cell Traits Shape Production Economics

Faster growth, lower input requirements, and greater metabolic efficiency can reduce production costs. Stability and stress resistance can improve consistency at scale, while control over fat, flavor, and nutrition can increase product value.

Traits That Drive Performance

Illustrative, Non-Exhaustive Examples



High-Performance Cell Lines Must Be Engineered.


Commercial production demands more from cells than they can naturally deliver. Livestock Labs methodically builds in the capabilities needed for lower costs, reliable production, and better products, then upgrades them as customer needs evolve.

THE BUSINESS MODEL

We Make the Cells. Our Customers Make the Products.

We source, engineer, validate, and **continuously upgrade** animal cell lines. We own these lines and license customers around the world the rights to use them. Each line can serve many customers across multiple markets with limited incremental cost, supporting **high gross margins**.

Capital-Efficient by Design



Scalability of software.
Defensibility of biology.

THE TRACTION

We're Already Solving Difficult Cell-Line Challenges

Platform Progress

o Cell Lines Ranked




3 Engineered

International Reach

Cells at Work in Five Countries

United States • Canada • India • Japan • Singapore



Custom Projects

2

Paid engineering
projects completed



Customer Validation

“Another company had already attempted
our cell-engineering project and failed.

Livestock Labs took on the same challenge
and succeeded, delivering the engineered
cell line we needed.”

George Engelmayr, PhD

Founder & CEO, Cultivated Biomaterials

25+ years in tissue engineering • 8 years in cellular agriculture • 4,700+ citations
Former CSO, Mission Barns • Experience at MIT, Duke, UPSIDE Foods & VitroLabs

WHY THIS TEAM

Built by Cultivated Meat Veterans.

Experience from two of the industry's pioneering companies.

THE CELL-ENGINEER

EX-NEW AGE EATS



Dr. Steen Ooi
CO-FOUNDER, CEO & CSO

Former Lead Scientist,
Porcine Cell Engineering

CULTIVATED MEAT EXPERIENCE
25+ years in cell and genome
engineering.

ACADEMIC PEDIGREE
Former scientist at UCLA, UCL,
Cancer Institute, and Columbia.
Published in Nature, Science, Cell,
and other leading journals.
Ph.D. Biochemistry (UCL); BA,
Natural Sciences/Genetics
(Cambridge)

BUILDS THE PLATFORM
Cell engineering • R&D •
Scientific strategy • IP

THE BUSINESS LEAD

EX-MISSION BARN'S



Andrew Sayles
CO-FOUNDER & COO

GLOBAL BUSINESS
DEVELOPMENT LEAD

CULTIVATED MEAT EXPERIENCE
Early business leader at Mission
Barns, the first cultivated-perk
company cleared by FDA and USDA.
Led functions spanning operations,
finance, R&D, supply chain, IT, and
facilities.

BUILDS THE BUSINESS
Customers • Partnerships •
Fundraising • Operations

COMMERCIAL EXECUTION
Led R&D across 100+ customers in
a business that routinely achieved
record growth. FIRST AMT'S CUSTOMER

THE technical depth to engineer it. The industry experience to commercialize it.

BACKED BEFORE THIS ROUND

\$950K+

TOTAL CAPITAL & SUPPORT

\$750K+

INVESTMENT CAPITAL



~\$200K

GRANT SUPPORT



ADVISED BY INDUSTRY & REGULATORY LEADERS

Eric Schulze, PhD
Former FDA regulator
Former VP at UPSIDE Foods

Larisa Rudenko, PhD, DABT
Former FDA Senior Adviser
for Biotechnology

Laura Plunkett, PhD, DABT
Board-certified toxicologist
Registered patent agent

THE COMPETITION

Built to Go Further

COMMON CELL-LINE STRATEGIES

Partial Solutions. Limited Control.

- **PRIMARY CELLS** Starting biology. Development burden remains.
- **SPONTANEOUS ADAPTATION** Changes occur without precise control.
- **SINGLE-TRAIT EDITING** One modification at a time. Scale requires many traits.
- **PLURIPOTENT CELLS** Flexible biology. More complex path to fat or muscle.

LIVESTOCK LABS

TARGETED MULTI-TRAIT PLATFORM

BUILT FOR LONG-TERM LEADERSHIP

- **TARGETED ENGINEERING** Precise control at known genomic sites.
- **MULTI-TRAIT DESIGN** Multiple traits combined in one stable line.
- **UPGRADEABLE ARCHITECTURE** Add or exchange traits without starting over.
- **ADULT PROGENITOR CELLS** Start biologically closer to fat or muscle.

We evaluated the major development strategies.
We chose the platform built for control, upgradeability, and scale.

THE COMPETITIVE ADVANTAGE

WHY WE GET HARDER TO CATCH

BIOLOGICAL HEAD START

Cell lines take years to source, engineer, clone, validate, and document. Biology takes time. Capital cannot skip it.

SINGULAR FOCUS

Cell lines are our sole focus, not an add-on. Every development effort advances their performance.

COMPOUNDING CELL LIBRARY

Every new line, trait, and customer validation expands our reusable IP, data, and engineering know-how.

CAPITAL EFFICIENCY

Small lab. Lean team. Capital builds reusable cell assets instead of factories or consumer brands.

THE MARKET

Trillion-Dollar Markets.
A \$542 Billion Cell-Line Opportunity

THE MARKETS CELL-BASED PRODUCTION COULD TRANSFORM

\$4.59T

PROJECTED 2030 MARKET LANDSCAPE



THE CELL-LINE OPPORTUNITY WITHIN

\$542B

MODELED 2030 TAM FOR CELL-LINE SUPPLIERS*
Assumes full cell-based adoption

ONE PLATFORM. SEVEN INDUSTRIES

Meat & Seafood • Pet Food • Leather • Nutraceuticals •
Cosmetics • Biopharma • Regenerative Medicine

140+

OUR BEACHHEAD

Cultivated meat companies and technology providers
Plus universities and research institutions

The industries are enormous. The cell-line layer is just beginning.

*Modeled TAM, not a forecast. Assumes full cell-based adoption and estimated cell-line supplier shares of 1-20% by sector. Represents market potential, not expected adoption or Livestock Labs revenue. Based on a 2024 market analysis commissioned by Livestock Labs.

WHY NOW

A New Era. A Foundational Opportunity.

The Rise of Specialized Suppliers

The shift from vertical integration to specialization is opening a market we're built to capture.

More Powerful Tools. More Valuable Cells.

Advances in genetic engineering and AI expand the traits we can design, engineer, and license.

A Head Start on Commercialization

Becoming the cell supplier customers choose in R&D and grow with into commercial production.

Scale Comes Next.

The Opportunity to Get In Is **Now**.

WHAT YOUR INVESTMENT UNLOCKS

Turn Proven Gene Control Into Powerful Cell Traits.

Exceptional quality. Lower costs. Production at scale.
Gene control is the foundation for engineering all three. We created a novel genetic switch to turn selected genes on and off. Your investment helps unlock its potential and transform an entire industry.



PROGRAM CELL BEHAVIOR

Extend proven gene control to complex cell traits that improve production efficiency.



EXPAND THE CELL LIBRARY

More species, tissue types, and validated cell lines.



TURN DEMAND INTO DEALS

Convert interest into paid engineering work and licenses.



PROTECT THE PLATFORM

File patent applications and safeguard proprietary technology.

18-MONTH TARGETS AT THE MAXIMUM RAISE

9

ENGINEERED, LICENSE
READY CELL LINES

\$1M+

DEAL
PIPELINE

2+

COMMERCIALY VALUABLE
TRAITS VALIDATED

The milestones designed to power Livestock Labs' next institutional round.

Forward-looking projections cannot be guaranteed.

OPPORTUNITY

The Potential for Substantial Returns

Three Paths to an Exit



Acquisition

A buyer acquires Livestock Labs. Investors share in the proceeds under their investment terms.



IPO

A public listing opens a path to selling shares on the stock market.



Secondary Sales

Investors sell their holdings to new investors in a private transaction.

Back the vision. Share in the upside.

OWN THE FUTURE

Meat Isn't Going Away. Nor Should It.

We're not taking meat off the table.
We're engineering the cells to put better meat on it.

Transform a Trillion-Dollar Industry

Reinventing animal agriculture

Build the Foundation

Capital-efficient cell-line platform

Unlock Global Demand

Better economics, taste, and nutrition

Get a *Stake* in the Future of Meat.